Consulta: subjectFacets:"Single dose"
Registros recuperados: 2
Data/hora: 10/06/2024 17:10:13

A comparative study of single-dose treatment of chancroid using thiamphenicol versus Azithromycin
Provedor de dados: Brazilian Journal of Infectious Diseases
Autores: B. Junior,Walter; Di Chiacchio,Nilton G.; Di Chiacchio,Nilton; Romiti,Ricardo; Criado,Paulo R.; Velho,Paulo Eduardo N. Ferreira.
A study was conducted in São Paulo, Brazil, to compare azithromycin with thiamphenicol for the single-dose treatment of chancroid. In all, 54 men with chancroid were tested. The etiology was determined by clinical characterization and direct bacterioscopy with Gram staining. None of the patients had positive serology or dark-field examination indicating active infection with Treponema pallidum. Genital infections due to Neisseria gonorrhoeae and herpes simplex virus were excluded by polymerase chain reaction testing. For 54 patients with chancroid, cure rates with single-dose treatment were 73% with azithromycin and 89% with thiamphenicol. HIV seropositivity was found to be associated with treatment failure (p=0.001). The treatment failed in all HIV...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Azithromycin; Chancroid; Haemophilus ducreyi; Single dose; Thiamphenicol.
Ano: 2009
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702009000300012

Pharmacokinetics and safety of repirinast tablets in healthy Chinese subjects
Provedor de dados: Brazilian Journal of Pharmaceutical Sciences
Autores: Lv,Cheng-zhe; Huang,Ming; Zhang,Quan-ying; Zong,Shun-lin; Wang,Meng.
ABSTRACT Repirinast is a new, synthetic, disodium cromoglycate-like antiallergic agent for oral administration in humans. This study evaluated the safety, tolerability and pharmacokinetics of repirinast tablets in healthy Chinese volunteers. This was a phase I, open-label, randomized, single- and multiple-dose study. Subjects were assigned to receive a single dose of repirinast tablet at either 150, 300, or 450 mg, or multiple doses of 150 mg twice daily for 5 days. Plasma samples were analyzed with LC-MS/MS. Pharmacokinetic parameters of active metabolite MY-1250 (deesterified repirinast) were calculated using non-compartmental analysis with WinNonlin software. Statistical analysis was performed using SPSS software. All adverse events (AEs) were mild and...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Repirinast/safety/pharmacokinetics; Single dose; Multiple dose; China.
Ano: 2018
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502018000200625